Hoth Therapeutics, Inc. (HOTH) Stock Score, Valuation & Financial Research

Hoth Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for HOTH

Hoth Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.80. These figures are a research snapshot, not a buy or sell recommendation.

What Hoth Therapeutics, Inc. does

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Hoth Therapeutics is a clinical-stage biopharmaceutical company that operates as a research and development entity. It does not currently generate revenue from product sales, as its therapeutic candidates are in various stages of pre-clinical and clinical development, and it relies on capital raises and strategic financing to fund its operations.

Products and services

  • The company focuses on developing therapeutic candidates including HT-001 for cancer treatment side effects, HT-003 for mast cell-related diseases, and other pipeline assets targeting inflammatory, oncological, and rare diseases.

Customer types

Patients with unmet medical needs in inflammatory, oncological, and rare disease areas.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct pre-clinical and clinical trials. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting unmet medical needs Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

HOTH financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.80
Market capitalization:
10.62M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -13.32M
Free cash flow:
USD -9.8M
Cash:
USD 7.89M
Total debt:
USD 5.68K
EPS:
USD -0.83

What stands out

  • Free cash flow is USD -9.8M, negative for the stored period.
  • The balance sheet shows USD 7.89M of cash versus USD 5.68K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 7.89M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for HOTH

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can HOTH fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is HOTH likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for HOTH to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of HOTH's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research HOTH

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.